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Abstract: Cyclooxygenase-2 (COX-2) overexpression is asso-
ciated with a poor prognosis in non–small-cell lung cancer 
(NSCLC) and may promote resistance to epidermal growth factor 
receptor inhibitors. This randomized phase 2 trial evaluated apri-
coxib, a novel COX-2 inhibitor, in combination with erlotinib in 
 biomarker-selected patients. Patients with stage IIIB/IV NSCLC 
previously treated with platinum-based chemotherapy were ran-
domized (2:1) to 400 mg/day apricoxib plus 150 mg/day erlotinib 
(AP/E) or placebo plus erlotinib (P/E) in 21-day cycles until disease 
progression or unacceptable toxicity. The primary endpoint was 
time to progression (TTP). A decrease of 50% or more from baseline 
urinary prostaglandin E
2
 metabolite after a 5-day,  open-label, run-
in period was used to select eligible patients. One hundred twenty 
patients (median age 64 years) were randomized (78 to AP/E and 
42 to P/E). Overall median TTP was 1.8 months in the AP/E group 
and 2.1 months in the P/E group, with a 12% objective response 
rate in both groups (intent-to-treat analysis). A subgroup analysis 
in patients aged 65 years or younger demonstrated a statistically 
significant TTP benefit for AP/E (hazard ratio 0.5 [95% confidence 
interval: not applicable–0.9]; p=0.018) and overall survival advan-
tage at minimum 1-year follow-up (median 12.2 versus 4.0 months; 
hazard ratio=0.5; p=0.021). The most common adverse events were 
rash, diarrhea, fatigue, and nausea. Toxicity contributed to early 
discontinuations in patients aged more than 65 years treated with 
AP/E. This is the first randomized placebo-controlled study of a 
COX-2 inhibitor in NSCLC to use a prospective patient-selection 
strategy. Although AP/E seemed to improve TTP and overall sur-
vival in a subset of patients aged 65 years or younger, the primary 
endpoint of the trial was not met.
Key Words: Non–small-cell lung cancer, Apricoxib, Erlotinib, 
Cyclooxygenase-2 inhibitor, Prostaglandin E
2
 metabolite.
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Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors such as erlotinib and gefitinib have demon-
strated clinical activity in NSCLC patients with activating 
EGFR mutations,1 and after platinum-based chemotherapy in 
unselected patients.2
Preclinical and clinical evidence suggest that hyperac-
tivity of cyclooxygenase-2 (COX-2) may confer resistance to 
EGFR inhibitors.3,4 COX-2 is overexpressed in 70% to 80% of 
patients with NSCLC and is associated with a poor prognosis.3 
To date, however, phase 2 studies combining celecoxib with 
either erlotinib or gefitinib in unselected patients with previ-
ously treated NSCLC have not demonstrated improvements in 
efficacy over an EGFR inhibitor alone.5
Apricoxib is a novel, selective COX-2 inhibitor that 
has demonstrated potent antitumor effects in animal models. 
Only those tumors with elevated COX-2 activity, which pro-
duced high levels of prostaglandin E
2
 (PGE
2
), were respon-
sive to the antitumor effects of apricoxib6,7; suggesting that 
a  biomarker-driven patient-selection strategy might improve 
efficacy in the clinic. Intratumoral PGE
2
 levels have been 
shown to correlate with the stable urinary metabolite of 
PGE
2
 (PGE-M).8 Moreover, an association has been observed 
between a decrease from baseline in urinary PGE-M and 
response to celecoxib plus chemotherapy.8,9 A phase I trial 
demonstrated that apricoxib at daily doses up to 400 mg was 
well tolerated in combination with erlotinib (150 mg/day) in 
patients with advanced NSCLC.10
The current, prospective, randomized, double-blind, 
phase II study was designed to test whether the addition of 
apricoxib (400 mg/day) to erlotinib would improve time to 
disease progression (TTP) in biomarker-selected patients with 
recurrent stage IIIB/IV NSCLC. Selection of patients for this 
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study was based on a 50% decrease from baseline urinary 
PGE-M in response to apricoxib.
PATIENTS AND METHODS
Patient Selection
Adult patients (≥18 years of age) with stage IIIB (pleu-
ral effusion; 6th edition of the American Joint Committee on 
Cancer) or IV NSCLC and measurable disease by Response 
Evaluation Criteria in Solid Tumors who had failed at 
least 1 prior platinum-based chemotherapy regimen were 
enrolled in this study. Eligible patients also had an Eastern 
Cooperative Oncology Group (ECOG) performance status 
(PS) of 0 to 2 and adequate renal, hepatic, and bone mar-
row function. By protocol amendment, patients with ECOG 
PS 2 were subsequently excluded after the Data Safety 
Monitoring Committee detected increased toxicity in these 
patients (n=6). Patients with central nervous system metas-
tases were eligible if asymptomatic, and off steroids after 
radiotherapy for 2 weeks or more. Patients were ineligible 
if they had received prior treatment with an EGFR tyrosine 
kinase inhibitor or had a history of significant cardiovascular 
disease or upper gastrointestinal bleeding.
Study Design and Treatment
This was a multi-institutional phase II trial. Patients 
entered an open-label run-in period where they received 
single-agent apricoxib (400 mg/day) for 5 consecutive days. 
Urinary PGE-M was measured on the first and last day of the 
run-in period. Patients with at least a 50% decrease from base-
line were randomized 2:1 to apricoxib (400 mg/day) plus erlo-
tinib (150 mg/day) or placebo plus erlotinib on 21-day cycles. 
The primary efficacy endpoint was TTP. Secondary endpoints 
included overall response, progression-free survival (PFS), 
overall survival (OS), safety, and biomarker analysis (COX-2 
expression and urinary PGE-M).
Patients were evaluated at baseline, on day 1 of every 
even-numbered cycle, for tumor response according to 
Response Evaluation Criteria in Solid Tumors version 1.0.11 
Safety was assessed using National Cancer Institute Common 
Toxicity Criteria version 3.0. Urinary PGE-M was assessed at 
baseline and on day 1 of cycles 2 and 3.
The sample size was determined to achieve 80% power 
to detect a 40% improvement in TTP corresponding to a Cox 
proportional hazard ratio (HR) of 1.4 by one-sided log-rank 
test with an α error of 0.20. The original sample size was 115, 
and this was increased to 122 by amendment excluding enroll-
ment of patients with an ECOG PS of 2.
RESULTS
Patients
A total of 176 patients were enrolled into the 5-day 
 open-label run-in period (Fig. 1). Of these, 120 patients 
Enrolled in open-label run-in
(N = 176)
Randomly assigned
(n = 120)
Excluded (n = 56)
Not eligible (n = 31)
Withdrew consent (n = 7)
Adverse event (n = 6)
Progressive disease (n = 3)
Noncompliance (n = 2)
Investigator decision (n = 1)
Other (n = 6)
Assigned to AP/E arm (n = 78)
Treated with AP/E (n = 78)
Assigned to P/E arm (n = 42)
Treated with P/E (n = 42)
Lost to follow-up (n = 0)
Discontinued AP/E (n = 74)
Disease progression (n = 46)
Adverse event (n = 16)
Withdrew consent (n = 3)
Death (n = 5)
Investigator decision (n = 1)
Other (n = 3)
Lost to follow-up (n = 0)
Discontinued P/E (n = 39)
Disease progression (n = 31)
Adverse event (n = 3)
Withdrew consent (n = 2)
Death (n = 0)
Investigator decision (n = 1)
Other (n = 2)
Analyzed in ITT population (n = 75)
Excluded (PS = 2) (n = 3)
Analyzed in ITT population (n = 39)
Excluded (PS = 2) (n = 3)
FIGURE 1.  Consolidated Standards of 
Reporting Trials (CONSORT) diagram. P/E, 
placebo plus erlotinib; AP/E, apricoxib plus 
150 mg/day erlotinib; ITT, intent-to-treat; 
PS, performance status.
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(68%) who exhibited a decrease of 50% or more from base-
line urinary PGE-M on day 5 were randomized to treatment 
with apricoxib plus erlotinib (AP/E group; n = 78) or placebo 
plus erlotinib (P/E group; n = 42). Baseline patient and dis-
ease characteristics for all randomized patients are shown 
in Table 1. Median age was 64 years. The primary reason 
for study discontinuation was disease progression (59% of 
patients in the AP/E group and 74% of patients in the P/E 
group). During the  double-blind period, 16 patients (20%) 
in the AP/E group discontinued because of adverse events 
compared with three (7%) in the P/E group. Overall, 41% of 
AP/E-treated patients and 33% of P/E-treated patients had a 
delay or dose modification.
Efficacy Analysis
The intent-to-treat (ITT) analysis included 75 patients 
in the AP/E group and 39 patients in the P/E group with 
an ECOG PS of 0 or 1. Prespecified covariate analyses of 
TTP, PFS, OS, best overall response, and disease control 
rate (DCR) were conducted using factors such as sex, age, 
ECOG PS, smoking status, disease stage, and biomark-
ers. Among these covariates, younger age (≤60 versus >60 
years; protocol specified) emerged as a significant factor 
(interaction p = 0.012) associated with longer TTP in the 
AP/E group, and this was also consistently observed for 
secondary endpoints. However, on extending the analysis it 
was observed that patients up to 65 years of age seemed to 
benefit from treatment with AP/E; therefore, efficacy analy-
ses are also reported for the subgroups (age ≤65 years and 
>65 years; interaction p = 0.009). Baseline characteristics 
in these subgroups were balanced between treatment groups 
and similar to those of the ITT population.
At the time of the primary analysis of TTP, all random-
ized patients had been followed up for at least 5 months; median 
TTP was 1.8 months in the AP/E group and 2.1 months in the 
P/E group (Table 2 and Fig. 2). In contrast, among patients 
aged 65 years or younger, median TTP was 2.7 months in 
the AP/E group compared with 1.4 months in the P/E group 
(HR = 0.5 [95% confidence interval: not applicable (NA)–
0.9]; p = 0.018). Results of the PFS analysis were nearly iden-
tical and are not reported. At the time of the OS analysis, all 
patients had at least 1 year of follow-up, and median OS in the 
subset of patients aged 65 years or younger was 12.2 months 
in the AP/E group compared with 4.0 months in the P/E group 
(HR = 0.5 [95% confidence interval: NA–0.9]; p = 0.021). In 
contrast, patients more than 65 years of age randomized to 
AP/E had worse outcomes compared with the P/E group for 
both TTP and OS (Table 2).
Best overall response and DCR is shown in Table 3. In 
the ITT population, nine patients (12%) in the AP/E group had 
a partial response with a median duration of 8.6 months, and 
TABLE 2.  Time to Progression and Overall Survival for 
Intent-to-Treat Population and Prespecified Subgroups by Age
Median
HR (95% CI)
Log-Rank 
p ValueP/E AP/E
Intent-to-treat populationa n = 39 n = 75
  Median TTP, months 2.1 1.8 1.0 (NA, 1.4) 0.438
  Median OS,b months 6.4 7.4 0.9 (NA, 1.4) 0.390
Patients ≤65 years of age n = 20 n = 45
  Median TTP, months 1.4 2.7 0.5 (NA, 0.9) 0.018
  Median OS,b months 4.0 12.2 0.5 (NA, 0.9) 0.021
Patients >65 years of age n = 19 n = 30
  Median TTP, months 4.7 1.4 2.0 (NA, 3.9) 0.958
  Median OS,b months 9.1 4.3 1.7 (NA, 3.0) 0.949
aIntent-to-treat population included only patients with Eastern Cooperative Oncology 
Group performance status of 0 or 1.
bOS analysis conducted when all patients had at least 1 year of follow-up.
P/E, placebo plus erlotinib; AP/E, apricoxib plus 150 mg/day erlotinib; HR, hazard 
ratio; CI, confidence interval; TTP, time to progression; OS, overall survival; NA, not 
applicable. 
TABLE 1.  Baseline Patient and Disease Characteristics
P/E (n = 42) AP/E (n = 78) All (N = 120)
Median age, years (range) 65 (36–84) 63 (35–81) 64 (35–84)
Age category, n (%)
  ≤ 65 years 23 (55) 46 (59) 69 (58)
  > 65 years 19 (45) 32 (41) 51 (42)
Sex, n (%)
  Male 25 (60) 42 (56) 67 (56)
  Female 17 (40) 36 (44) 53 (44)
ECOG performance  
status, n (%)
  0 or 1 39 (93) 75 (96) 114 (95)
  2 3 (7) 3 (4) 6 (5)
Never smoker, n (%) 6 (14) 9 (12) 15 (13)
Histology, n (%)
  Adenocarcinoma 24 (57) 45 (58) 69 (57)
  Squamous cell carcinoma 11 (26) 21 (27) 32 (27)
  Bronchioalveolar carcinoma 0 3 (4) 3 (3)
  Other or unknown 7 (17) 9 (11) 16 (13)
Disease stage, n (%)
  IIIB (pleural effusion) 2 (5) 13 (17) 15 (13)
  IV 40 (95) 65 (83) 105 (88)
Baseline urinary  
PGE-M, n (%)
  Normal 6 (14) 12 (15) 18 (15)
  Elevated 36 (86) 66 (85) 102 (85)
EGFR mutation, n (%)
  Yes 0 2 (3) 2 (2)
  No 13 (31) 20 (26) 33 (27)
  Unknown 29 (69) 56 (72) 85 (71)
KRAS mutation, n (%)
  Yes 1 (2) 8 (10) 9 (7)
  No 14 (33) 18 (23) 32 (27)
  Unknown 27 (64) 52 (67) 79 (66)
COX-2 IHC index
  N 9 14 23
  Mean (SD) 7.0 (3.1) 5.8 (3.2) 6.3 (3.2)
ECOG, Eastern Cooperative Oncology Group; PGE-M, prostaglandin E
2
 metabolite; 
EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene 
homolog; COX-2, cyclooxygenase-2; IHC, immunohistochemistry.
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five patients (13%) in the P/E group had either a complete or 
partial response with a median duration of 7.4 months. The 
DCR was also similar in both treatment groups. In contrast, 
among patients aged 65 years or younger, best overall response 
was significantly higher in the AP/E group compared with the 
P/E group (p = 0.036), and DCR was also significantly higher 
in the AP/E group (p = 0.018).
Safety
The incidence of adverse events (AEs) was similar in 
both treatment groups (Table 4), but those events of grade 
3 or higher were more frequent in the AP/E arm. Patients in 
the AP/E group had a higher incidence of fatigue, cough, and 
increased serum creatinine (observed in the AP/E group only), 
whereas patients in the P/E group had a higher incidence of 
anorexia, acneiform rash, and pruritus.
Seventeen patients (14%) had a treatment-related seri-
ous adverse event (SAE), including 13 patients (17%) in the 
AP/E group and four patients (10%) in the P/E group. Although 
there were more gastrointestinal SAEs in the AP/E group (6 
versus 1), only one patient in each treatment group had gastro-
intestinal hemorrhage, and two patients in the AP/E group had 
a gastric or intestinal ulcer perforation. Seven patients in the 
FIGURE 2.  Kaplan–Meier estimate of time to progression by treatment group in the intent-to-treat population (A) and among 
patients ≤65 years of age (B). Kaplan–Meier estimate of overall survival by treatment group in the intent-to-treat population 
(C) and among patients ≤65 years of age (D). P/E, placebo plus erlotinib; AP/E, apricoxib plus 150 mg/day erlotinib; HR, hazard 
ratio; CI, confidence interval, NA, not applicable.
TABLE 3.  Best Overall Response and Tumor Control Rate
Patients, n (%)
P/E AP/E
Intent-to-Treat Populationa n = 39 n = 75
  CR 1 (3) 0
  PR 4 (10) 9 (12)
  SD ≥6 weeks 13 (33) 29 (39)
  Disease control 
(CR+PR+SD ≥6 weeks)
18 (46) 38 (51)
Evaluable patients ≤65  
years of age
n = 20 n = 45
  CR 0 0
  PR 1 (5) 8 (18)b
  SD 6 (30) 19 (42)
  Disease control 7 (35) 27 (60)c
aIntent-to-treat population included only patients with Eastern Cooperative Oncology 
Group performance status of 0 or 1.
bp = 0.036 based on a proportional odds model (adjusted for smoking status) 
comparing tumor responses between P/E and AP/E.
cp = 0.018 based on a logistic regression model (adjusted for smoking status) 
comparing the disease control rate between P/E and AP/E.
P/E, placebo plus erlotinib; AP/E, apricoxib plus 150 mg/day erlotinib; CR, complete 
response; PR, partial response; SD, stable disease.
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AP/E group died while on study treatment compared with one 
death in the P/E group, and three of those deaths were attrib-
uted to SAEs of cerebral infarction, cerebrovascular accident, 
or pulmonary fibrosis.
Patients more than 65 years of age had more SAEs and 
more early discontinuations because of AEs than patients aged 
65 years or younger. In the AP/E group, 62% of patients aged 
more than 65 years compared with 35% of patients aged 65 
years or younger had an SAE during double-blind treatment. 
Similarly, in the P/E group 42% and 22% had an SAE, respec-
tively. The majority of patients who discontinued study drug 
because of AEs were more than 65 years of age (13 in the 
AP/E group and 3 in the P/E group).
Biomarker Analysis
Among 35 patients tested for EGFR mutations, 33 were 
EGFR wild type, and two patients in the AP/E group had 
EGFR mutations. Among 41 patients successfully tested for 
K-ras mutations, 32 were wild type and nine had a mutation. 
K-ras mutations were present in eight patients in the AP/E 
group and one patient in the P/E group. Notably, among 
patients with K-ras mutations in the AP/E group, two had 
PR. The majority of tumors tested (n = 23) expressed high 
levels of COX-2 as indicated by an immunohistochemistry 
index 4 or more, and 85% of patients screened had elevated 
baseline urinary PGE-M.
DISCUSSION
Selecting patients for treatment with targeted agents based 
on tumor biology can enrich the population with patients who 
are most likely to benefit. This concept was recently validated in 
NSCLC patients with activating EGFR mutations, where treat-
ment with erlotinib or gefitinib produced higher response rates 
and improved PFS than first-line chemotherapy.1,12 Selection of 
patients for the current study based on modulation of urinary 
PGE-M was implemented based on evidence that patients who 
exhibited a decrease from baseline PGE-M in response to treat-
ment with celecoxib plus chemotherapy were more likely to 
receive clinical benefit.8,9,13 In addition, increased intratumoral 
COX-2 expression was significantly associated with improved 
PFS in NSCLC patients treated with celecoxib plus erlotinib.14 
Taken together, these studies suggest that overexpression of 
COX-2 and/or a biochemical response to a COX-2 inhibitor 
may identify NSCLC patients who are more likely to benefit 
from addition of a COX-2 inhibitor to standard agents. COX-2 
activity has also been linked to epithelial mesenchymal tran-
sition,12–14 which is associated with increased metastasis and 
resistance to EGFR TKIs.6,7 Strikingly, addition of apricoxib 
to an erlotinib regimen abolished all metastatic spread in two 
COX-2–overexpressing orthotopic pancreatic cancer models 
but did not improve outcomes in COX-2–independent models.14 
Therefore, apricoxib may inhibit tumor progression and over-
come resistance to erlotinib in tumors with hyperactive COX-2.
TABLE 4.  Treatment Emergent Adverse Events Occurring in >10% of Patients During Double-Blind Period
Preferred Term
Patients, n (%)
P/E (n = 42) AP/E (n = 78)
All Grades Grade ≥3 All Grades Grade ≥3
Rash 23 (55) 2 (5) 42 (54) 3 (4)
Diarrhea 25 (60) 1 (2) 41 (53) 5 (6)
Fatigue 12 (29) 1 (2) 33 (42) 3 (4)
Nausea 12 (29) 0 27 (35) 0
Dry skin 11 (26) 0 20 (26) 0
Cough  5 (12) 0 18 (23) 0
Anorexia 15 (36) 1 (2) 17 (22) 2 (3)
Dyspnea 11 (26) 3 (7) 16 (21) 4 (5)
Vomiting  4 (10) 0 16 (21) 1 (1)
Mucositis  4 (10) 0 15 (19) 2 (3)
Acneform rash 11 (26) 1 (2) 13 (17) 2 (3)
Constipation  5 (12) 0 12 (15) 0
Insomnia  7 (17) 0 11 (14) 0
Dizziness  4 (10) 0 10 (13) 0
Dyspepsia  6 (14) 0 10 (13) 1 (1)
Pruritis  9 (21) 0 10 (13) 2 (3)
Anemia 2 (5) 0  9 (12) 4 (5)
Increased serum creatinine 0 0  9 (12) 1 (1)
Weight loss  6 (14) 0  9 (12) 0
Peripheral edema  6 (14) 0  8 (10) 0
Back pain  5 (12) 3 (7) 7 (9) 2 (3)
Abdominal pain 5 (12) 2 (5) 5 (6) 2 (3)
P/E, placebo plus erlotinib; AP/E, apricoxib plus 150 mg/day erlotinib.
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This is the first randomized placebo-controlled 
study of a COX-2 inhibitor in NSCLC to use a prospective 
 patient-selection strategy. This is a unique patient population, 
able to modulate urinary PGE-M in response to a COX-2 
inhibitor that has never before been studied. The primary end-
point of the study was not met, with no difference between 
treatment groups in the ITT analysis with respect to TTP or 
secondary endpoints. In a subset analysis of patients aged 
65 years or younger, the combination of AP/E demonstrated 
statistically significant benefit based on TTP, OS, and DCR 
compared with P/E. In contrast, patients aged more than 65 
years randomized to AP/E had worse toxicity, TTP, and OS 
compared with the P/E group.
In general, the combination of apricoxib plus erlo-
tinib was tolerated in the majority of patients; however, there 
were more discontinuations because of AEs and three deaths 
because of SAEs in the AP/E group. The increase in serum 
creatinine observed in the AP/E group is consistent with the 
toxicology of COX-2 inhibitors. However, patients aged more 
than 65 years had a higher incidence of SAEs and accounted 
for 75% of early discontinuations because of AEs, which may 
have contributed to the lack of clinical benefit in that subset. 
Our trial suggests that apricoxib may add to the toxicity of 
erlotinib, particularly in older patients and in those who had 
poor PS. Similar findings were reported in the BR.21 study of 
erlotinib in advanced NSCLC. In that study, a retrospective 
analysis by age (≥70 years and <70 years) showed that older 
patients were more likely to discontinue because of treatment-
related toxicity and received a lower dose intensity compared 
with younger patients.15
Even though this trial does not allow us to draw a defini-
tive conclusion about the role of a particular clinical charac-
teristic predictive of benefit, a phase 3 trial is being considered 
in a biomarker-selected population of NSCLC patients aged 
65 years or younger and with a PS lower than 2.
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